These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4716 related articles for article (PubMed ID: 6169659)

  • 21. [Immunological analysis of melanoma-specific antigen].
    Wakabayashi S; Okamoto S
    Nihon Hifuka Gakkai Zasshi; 1985 Oct; 95(11):1145-51. PubMed ID: 3879298
    [No Abstract]   [Full Text] [Related]  

  • 22. Murine monoclonal IgG3 to human colorectal tumor-associated antigens: enhancement of antibody-dependent cell-mediated cytotoxicity by interleukin 2.
    Morgan AC; Sullivan W; Graves S; Woodhouse CS
    Cancer Res; 1989 May; 49(10):2773-6. PubMed ID: 2785437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo tumor localization using tumor-specific monkey xenoantibody, alloantibody, and murine monoclonal xenoantibody.
    Stuhlmiller GM; Sullivan DC; Vervaert CE; Croker BP; Harris CC; Seigler HF
    Ann Surg; 1981 Nov; 194(5):592-601. PubMed ID: 6895297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas.
    Liao SK; Horton L; Flahart RE; O'Rear L; Crumpacker D; Imbaratto JW; Yannelli JR; Robinson RR; Oldham RK
    Hum Antibodies Hybridomas; 1990; 1(2):66-76. PubMed ID: 2103354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
    de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM
    Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity.
    Steplewski Z; Sun LK; Shearman CW; Ghrayeb J; Daddona P; Koprowski H
    Proc Natl Acad Sci U S A; 1988 Jul; 85(13):4852-6. PubMed ID: 3387441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Melanoma and immunity.
    Rheins LA; Nordlund JJ
    Immunol Ser; 1989; 46():769-87. PubMed ID: 2484957
    [No Abstract]   [Full Text] [Related]  

  • 28. Tumours can act as adjuvants for humoral immunity.
    Brown DM; Fisher TL; Wei C; Frelinger JG; Lord EM
    Immunology; 2001 Apr; 102(4):486-97. PubMed ID: 11328383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
    Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
    Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
    Drebin JA; Link VC; Greene MI
    Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-mediated killing of human tumor cells by attached effector cells.
    Hellström I; Garrigues U; Lavie E; Hellström KE
    Cancer Res; 1988 Feb; 48(3):624-7. PubMed ID: 3335025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density.
    Niwa R; Sakurada M; Kobayashi Y; Uehara A; Matsushima K; Ueda R; Nakamura K; Shitara K
    Clin Cancer Res; 2005 Mar; 11(6):2327-36. PubMed ID: 15788684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma.
    Munn DH; Cheung NK
    Cancer Res; 1987 Dec; 47(24 Pt 1):6600-5. PubMed ID: 3499978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues.
    Brown JP; Woodbury RG; Hart CE; Hellström I; Hellström KE
    Proc Natl Acad Sci U S A; 1981 Jan; 78(1):539-43. PubMed ID: 6165996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.
    Herlyn D; Koprowski H
    Proc Natl Acad Sci U S A; 1982 Aug; 79(15):4761-5. PubMed ID: 6289317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
    Masui H; Moroyama T; Mendelsohn J
    Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal antibodies to human tumor antigens.
    Steplewski Z
    Transplant Proc; 1980 Sep; 12(3):384-7. PubMed ID: 7222217
    [No Abstract]   [Full Text] [Related]  

  • 38. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.
    Woodhouse CS; Morgan AC
    Cancer Res; 1989 May; 49(10):2766-72. PubMed ID: 2713860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unusually efficient tumor cell lysis by human effectors of antibody-dependent cellular cytotoxicity mediated by monoclonal antibodies.
    Christiaansen JE; Sears DW
    Cancer Res; 1984 Sep; 44(9):3712-8. PubMed ID: 6744288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ADCC of cultured human melanoma cells: analysis with monoclonal antibodies to human melanoma-associated antigens.
    Imai K; Ng AK; Glassy MC; Ferrone S
    Scand J Immunol; 1981 Oct; 14(4):369-77. PubMed ID: 7336169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 236.